Following Consultation With FDA, Immunocore Converts The TEBE-AM Phase 2/3 Clinical Trial Into A Phase 3 Trial For Kimmtrak For Previously Treated Advanced Cutaneous Melanoma
Portfolio Pulse from Benzinga Newsdesk
Immunocore has announced the conversion of its TEBE-AM Phase 2/3 clinical trial into a Phase 3 trial for Kimmtrak, targeting previously treated advanced cutaneous melanoma, following consultation with the FDA.
May 29, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunocore has upgraded its TEBE-AM clinical trial to Phase 3 for Kimmtrak, aimed at treating advanced cutaneous melanoma, after discussions with the FDA.
The upgrade to a Phase 3 trial indicates significant progress and potential efficacy of Kimmtrak, which could lead to future FDA approval and market release, positively impacting Immunocore's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100